HIV-1 Tat Triggers Nuclear Localization of ZO-1 via Rho Signaling and cAMP Response Element-Binding Protein Activation

Yu Zhong  
*University of Kentucky, yu.zhong@uky.edu*

Bei Zhang  
*University of Kentucky, bei.zhang@uky.edu*

Sung Yong Eum  
*University of Kentucky, sungyong.eum@uky.edu*

Michal Toborek  
*University of Kentucky, mjtobo00@uky.edu*

Follow this and additional works at: [https://uknowledge.uky.edu/neurosurgery_facpub](https://uknowledge.uky.edu/neurosurgery_facpub)  
Part of the [Diseases Commons](https://uknowledge.uky.edu/diseases_commons), [Neuroscience and Neurobiology Commons](https://uknowledge.uky.edu/neuroscience_and_neurobiology_commons), and the [Neurosciences Commons](https://uknowledge.uky.edu/neurosciences_commons)

**Click here to let us know how access to this document benefits you.**

**Repository Citation**  
Zhong, Yu; Zhang, Bei; Eum, Sung Yong; and Toborek, Michal, "HIV-1 Tat Triggers Nuclear Localization of ZO-1 via Rho Signaling and cAMP Response Element-Binding Protein Activation" (2012). *Neurosurgery Faculty Publications*. 5.  
[https://uknowledge.uky.edu/neurosurgery_facpub/5](https://uknowledge.uky.edu/neurosurgery_facpub/5)

This Article is brought to you for free and open access by the Neurosurgery at UKnowledge. It has been accepted for inclusion in Neurosurgery Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
The human immunodeficiency virus (HIV)-specific protein trans-activator of transcription (Tat) can contribute to the dysfunction of brain endothelial cells and HIV trafficking into the brain by disrupting tight junction (TJ) integrity at the blood–brain barrier (BBB) level. Specific TJ proteins, such as zona occludens (ZO) proteins, localize not only at the cell–cell borders but are also present in the nuclei. The objective of the present study was to evaluate the mechanisms and significance of Tat-induced nuclear localization of ZO-1. Treatment of a brain endothelial cell line (hCMEC/D3 cells) with Tat resulted in a decrease in total levels of ZO-1 but significantly upregulated ZO-1 protein expression in the nuclei. In addition, exposure to Tat stimulated Rho signaling and induced phosphorylation and activity of transcription factor CAMP response element-binding protein (CREB), binding sites that have been identified in the proximal region of the ZO-1 promoter. Interestingly, inhibition of the Rho cascade protected against Tat-induced upregulation of ZO-1 in the nuclei and activation of CREB. Depletion of CREB by infection of cells with specific shRNA lentiviral particles attenuated both Tat-induced Rho signaling and nuclear targeting of ZO-1. A decrease in CREB levels also attenuated Tat-induced endothelial and BBB hyperpermeability as well as transendothelial migration of monocytic cells. The role of CREB in Tat-mediated alterations of ZO-1 was confirmed in brain microvessels in mice with CREB shRNA lentiviral particles injected into the cerebral circulation. The present results indicate the crucial role of Rho signaling and CREB in modulation of nuclear localization of ZO-1 and maintaining the integrity of endothelial monolayers.

Introduction
Disruption of endothelial tight junctions (TJs) is a feature of several acute and chronic brain disorders, including infection by human immunodeficiency virus-1 (HIV-1) (Dallasta et al., 1999; Boven et al., 2000). Because endothelial cells are not productively infected by HIV-1, several vascular effects of this virus are thought to be mediated by secondary mediators, including the HIV-1-specific protein Tat. Tat is taken up by the cells via insertion into the endosome membranes (Yezid et al., 2009), followed by localization into the nuclei (De Marco et al., 2010). In addition, we demonstrated that Tat, in a dose-dependent manner, can interact with cellular receptors (e.g., vascular endothelial growth factor receptor-2), activate small GTPases, and thus modulate TJ protein expression (András et al., 2005; Zhong et al., 2008, 2010).

Received Aug. 19, 2011; revised Oct. 17, 2011; accepted Nov. 5, 2011.
Author contributions: M.T. designed research; Y.Z., B.Z., and S.Y.E. performed research; Y.Z., B.Z., and S.Y.E. analyzed data; Y.Z. and M.T. wrote the paper.
This work was supported by National Institutes of Health Grants MH63022, MH072567, DA027569, and NS39254.
The authors declare no competing financial interests.
Correspondence should be addressed to Dr. Michal Toborek, Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, R. Bunn Gautier Building, Room 517, 1011 NW 15th Street, Miami, FL 33136. E-mail: mtoborek@med.miami.edu.
S. Y. Eum and M. Toborek’s present address: Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Miami, FL 33136.
DOI:10.1523/JNEUROSCI.4266-11.2012
Copyright © 2012 the authors 0270-6474/12/320143-08$15.00/0
din and claudin-5 and diminished transendothelial migration of HIV-1-infected monocytes (Persidsky et al., 2006).

The CAMP response element-binding protein (CREB) is a transcription factor activated by phosphorylation on Ser133. Recent reports provide evidence that CREB can be involved in regulation of epithelial junction function. Indeed, the transcriptional repression of ZO-1 by JunD appears to be mediated through a CREB-binding site within the proximal region of the ZO-1 promoter. In the present study, we focused on the signaling and transcriptional mechanisms that regulate nuclear targeting of ZO-1 by HIV-1 protein Tat. We demonstrate that exposure to Tat induces nuclear localization via activation of Rho signaling and activation of CREB binding to a ZO-1 promoter in brain endothelial cells. Importantly, depletion of CREB protected both against Tat-induced alterations of ZO-1 levels and disruption of endothelial integrity.

Materials and Methods

Cell cultures, infection with shRNA lentiviral particles, and Tat treatment. Human brain cortical microvessel endothelial cells (hCMEC/D3) (Weckler et al., 2005) were cultured as described previously (Zhong et al., 2008). Before exposure to treatment factors, hCMEC/D3 cells were incubated in EBME-2 medium without FBS and EGM-2 SingleQuots (Lonza) for 24 h. For transendothelial migration studies, cocultures of hCMEC/D3 with human monocytes (THP-1) cells were used. THP-1 cells were cultured in RPMI-1640 medium supplemented with 10% FBS.

For specific experiments, hCMEC/D3 cells were infected with shRNA lentiviral particles containing target-specific constructs encoding for CREB-1 (h) shRNA and control shRNA (both from Santa Cruz Biotechnology) using the instructions of the manufacturer. This procedure resulted in ~50% decrease in CREB expression. Stable cell lines were selected in a medium containing 10 μg/ml puromycin and maintained in the presence of puromycin in EBME-2 completed medium. The cells with decreased CREB expression were fully viable.

HIV-1 Tat protein was purified as described by Ma and Nath (1997). To determine specificity of Tat-induced effects, Tat solutions were immunoadsorbed using anti-Tat antibody conjugated to protein-A/G plus agarose (Santa Cruz Biotechnology), followed by centrifugation to remove precipitated proteins. This antibody–absorption mixture was named AA-Tat. Another control form of Tat was heat-inactivated Tat (H-Tat) obtained by heating the protein at 90°C for 1 h, which inactivates biological potentials of proteins but does not affect activity of endotoxins such as LPS.

Adenovirus infection. Recombinant adenovirus encoding for green fluorescent protein (GFP) and the Rho inhibitor Clotridium botulinum exoenzyme C3 transferease, the exoenzyme that specifically ribosylates and inhibits the function Rho gene, was produced as described previously (Hirai et al., 2007) and named the C3 adenovirus. A separate adenovirus vector expressing GFP without exoenzyme C3 transferease was constructed as a control (control adenovirus). The viruses were amplified by repeated infection into human embryonic kidney 293 cells. Media containing recombinant adenoviruses were collected and stored at −80°C. hCMEC/D3 cells were infected with recombinant adenoviruses at a multiplicity of infection of 200 in a 6 or 10 cm culture dish. Infection with adenoviruses resulted in efficiency close to 100% as determined by monitoring GFP signal under a fluorescent microscope.

Cell fractionation, immunoblots, and electrophoretic mobility shift assay. Cell fractions were obtained using a nuclear and cytoplasmic extraction reagents kit from Thermo Fisher Scientific and analyzed by Western blotting using standard approaches. The density of the bands was calculated with the Scion Image program. CREB, phosphorylated CREB (p-CREB) (Ser133), phosphoryl-mosino light chain 2 (MLC) (Ser19), and MLC2 antibodies were purchased from Cell Signaling Technologies. RhoA, vascular endothelial (VE)-cadherin, and all secondary antibodies were from Santa Cruz Biotechnology. ZO-1 and claudin-5 antibodies were from Invitrogen. MLC kinase (MYLK) and anti-actin antibodies were from Sigma.

For electrophoretic mobility shift assay (EMSA), synthetic oligonucleotides were produced and 5-biotinylated by Integrated DNA Technologies. The sequence for the wild-type CREB was 5′-CGG GGT GCC CAT GAC GT 3′ and for the mutant CREB was 5′-CGG GGT GCC CAT GAC GT 3′. Binding reactions were performed using a LightShift Chemiluminescent EMSA kit (Pierce) following the instructions of the manufacturer.

Results

Rho signaling differentially regulates Tat-induced alterations of total and nuclear ZO-1 expression

hCMEC/D3 cultures were treated with Tat for 15 h, and ZO-1 protein expression was evaluated in total cell lysates and nuclear extracts by Western blotting. As indicated in Figure 1A, treatment with Tat significantly decreased total ZO-1 levels in cells that were mock infected or infected with a control adenovirus. However, inhibition of Rho by adenovirus expressing exoenzyme C3 transferease (C3 adenovirus) markedly protected against Tat-induced alterations of ZO-1 levels. The observed effects were specific because infection with control adenovirus did not affect the basal levels of ZO-1. In addition, exposure to AA-Tat did not affect ZO-1 levels. Expression of actin (housekeeping protein) also was not affected by the infection procedure.

To further determine the relationship between the Rho signaling and ZO-1 expression, ROCK (the Rho downstream kinase) activity was inhibited by a 30 min pretreatment with Y27632 (4-[(1R)-1-aminomethyl]-N-pyridin-4-yl-cyclohexane-1-carboxamide) (5 μM). Similar to C3 adenovirus, treatment with Y27632...
immunoblotting with specific anti-phospho-CREB (Ser133) antibody, and the levels were normalized to t-CREB levels.

In cultures exposed to Tat plus Y27632, ZO-1 levels were detected in whole-cell lysates after a 15 h exposure (Fig. 2B). Confluent hCMEC/D3 cultures were pretreated with Y27632 (5 μM; ROCK inhibitor) for 30 min and then exposed to Tat (100 nM). ZO-1 levels were detected in whole-cell lysates at 1 h exposure (B) or in nuclear extracts at 1 h exposure (C) by immunoblotting. ZO-1 expression was normalized to actin levels. The blots reflect representative data from three different experiments (mean ± SD), and the bar graphs are quantified data from these experiments. *p < 0.05, **p < 0.01 or ***p < 0.001, compared with the respective control (vehicle-treated cells).†††p < 0.001, data in cultures exposed to Tat plus C3 adenovirus are significantly different from those in cultures exposed to Tat alone.

CREB probe (the lane before last) or unlabeled mutated probe (last lane). First lane (Neg), nuclear protein was not added to binding reaction. The images are representative blots, and the bar graphs are pooled densitometry data from three experiments (mean ± SD). **p < 0.01, compared with vehicle-treated cells.

Differences seen in nuclear fractions of mock or control adenovirus-infected hCMEC/D3 cells. These effects were completely prevented by the inhibition of Rho by C3 adenovirus (Fig. 1C) or inhibition of ROCK by a 30 min pretreatment with Y27632 (5 μM) (Fig. 1D). It is now well established that actin is present in the nuclei (Pederson, 2008) and its cytoplasmic and nuclear pools are linked (Hofmann, 2009). Therefore, the levels of nuclear actin were detected as internal controls.

To determine the specificity of ZO-1 responses, we determined the effects of Tat on cellular levels of VE-cadherin. hCMEC/D3 cells were characterized by strong cytoplasmic VE-cadherin expression, with virtually no presence in the nuclei. Tat exposure did not affect cellular VE-cadherin levels nor did it induce nuclear translocation of this protein (data not shown).

**Tat simulates CREB phosphorylation and binding activity**

Because CREB might be involved in transcriptional regulation of ZO-1 expression (Chen et al., 2008), we next evaluated the influence of Tat on CREB activation. Treatment of hCMEC/D3 cultures with Tat resulted in a time-dependent increase in p-CREB as determined by Western blotting. The most pronounced (~2.7-fold) induction of p-CREB levels was observed after a 1 h exposure to 100 nM Tat. Total CREB (t-CREB) levels did not change in response to Tat (Fig. 2A). We also evaluated CREB DNA binding activity using biotin-labeled oligonucleotide probe with the sequence specific for the CREB binding sites on ZO-1 promoter. Exposure to 100 nM Tat induced a time-dependent increase in CREB binding with the maximum effect at 1 h of treatment. The specificity of this effect was confirmed by a competition assay using a 100-fold molar excess of unlabeled wild-type or unlabeled mutated oligonucleotide probes. The CREB binding signal disappeared in the presence of an excess of the CREB wild-type competitor but was unaffected in the presence of a mutated competitor (Fig. 2B).

**Tat induces the interactions between the Rho and CREB pathways**

To evaluate a possible interaction between Rho signaling and CREB activity, a series of immunoprecipitation studies was performed using anti-CREB antibody. As indicated in Figure 3A, CREB immunoprecipitated with p-CREB, RhoA, MLC, and MYLK, a downstream kinase from Rho. Importantly, treatment with 100 nM Tat for 1 h markedly increased these interactions, reflecting increased phosphorylation of CREB and activation of the Rho pathway.
We then evaluated the involvement of Rho signaling in Tat-induced CREB DNA binding by blocking Rho pathways via infecting hCMEC/D3 cells with C3 adenovirus. Control cells were mock infected or infected with the control adenovirus. The cultures were then exposed to Tat for 1 h and CREB binding was determined in the nuclear proteins. As indicated in Figure 3B, treatment with Tat significantly increased CREB binding activity in control cultures. However, this effect was markedly attenuated by infection with C3 adenovirus. Tat-induced CREB binding was also prevented by pretreatment with ROCK inhibitor Y27632 (5 μM for 30 min) (data not shown). Finally, pretreatment with Y27632 or with MLCK inhibitor ML-9 [1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine] completely abolished Tat-mediated phosphorylation of CREB (Fig. 3C, D, respectively).

Next, we studied the influence of CREB on Rho signaling. Cellular CREB levels were depleted by infecting hCMEC/D3 cells with specific CREB shRNA lentiviral particles, whereas control cultures were infected with control shRNA lentivirus. This procedure resulted in an ~50% decrease in cellular CREB (data not shown). Importantly, CREB depletion inhibited Tat-mediated phosphorylation of MLC (Fig. 3E), indicating the dependency of the Rho pathway on CREB levels. Thus, the results in Figures 3 and 4 indicate that the Rho cascade closely interacted with CREB, resulting in cross-activation of these signaling pathways.

CREB activity is required for Tat-induced nuclear targeting of ZO-1
Because inhibition of the Rho pathway protected against Tat-induced nuclear localization of ZO-1 (Fig. 1C, D) and Rho closely interacts with CREB (Fig. 3), we next addressed the role of CREB in Tat-induced elevation of nuclear ZO-1 levels. The experiments were performed on hCMEC/D3 cells in which CREB was depleted by infection with specific CREB shRNA (CREB-sh). Consistent with the results shown in Figure 1, a decrease in total ZO-1 levels was observed in control cultures exposed to 100 nM Tat for 15 h (Fig. 4A); however, a 1 h Tat treatment caused an increase in nuclear ZO-1 (Fig. 4B). Importantly, depletion of CREB fully abolished these effects in both total cell lysates and nuclear fraction.

To further link these findings with CREB activation, we determined the effects of Tat on CREB phosphorylation and binding activity in control and CREB-depleted hCMEC/D3 cells. Using conditions established in experiments reflected in Figure 3, cells were treated with 100 nM Tat for 1 h. Tat-induced phosphorylation of CREB was completely inhibited in CREB-depleted cells (Fig. 4C). Similarly, Tat-stimulated CREB DNA binding activity...
fraction followed by treatment with Tat (100 nM) for 15 h (Fig. C). The final series of experiments determined the effects of CREB depletion on the functional status of endothelial monolayers. As indicated in Figure 6A, treatment with Tat (but not with AA-Tat and H-Tat) disrupted the endothelial barrier function as illustrated by increased FITC–dextran 20 flux across cultured hC-MEC/D3 monolayers. Importantly, CREB depletion by infecting the cells with CREB shRNA lentiviral particles significantly protected against these effects, mimicking in vivo results presented in Figure 5C. Similarly, CREB depletion completely protected against Tat-induced adhesion of monocytic cells to endothelial monolayers (Fig. 6B).

Discussion
Disruption of the integrity of the brain endothelium is well documented in HIV-1 infection. Clinical studies have reported the absence or fragmentation ofZO-1 and occludin in HIV-positive patients with encephalitis or HIV-1-associated dementia (Dallasta et al., 1999; Boven et al., 2000; Eugenin et al., 2006). To confirm the role of TJs in HIV-1-associated brain pathology, it has been shown that monocyte migration occurs between endothelial-cell borders and TJ disruption, correlated with the intensity of monocyte infiltration in human brain tissue with HIV encephalitis (Persidsky et al., 2006). In addition, monocyte infiltration has been associated with the disruption of ZO-1 immunoreactivity in HIV-positive patients (Boven et al., 2000). HIV-1 protein Tat has been shown to alter the expression of several TJ proteins, including occludin, claudin-5, ZO-1, and ZO-2 (Zhong et al., 2008). However, there is no information available on the effects of HIV-1 and/or HIV-1-specific proteins on nuclear localization of TJ proteins and on the regulatory mechanisms that control such localization.

Although HIV-1 has been shown to decrease cellular expression ofZO-1 in vitro and in an animal model (Luabea et al., 2000; Huang et al., 2009), novel results of the present study indicate that this effect is accompanied by a significant increase in nuclear levels ofZO-1. Moreover, inhibition of Rho signaling by C3 transferase or Y27632 protected against Tat-mediated alterations of nuclear localization ofZO-1. These results are in agreement with our previous report that Tat is a potent stimulator ofRho signaling in brain endothelial cells (Zhong et al., 2010). In addition, our findings are consistent with reports indicating a critical role of Rho in the regulation of TJ protein expression and TJ disassembly through activation of signaling pathways that regulate cytoskeletal organization.

Indeed, RhoA activation can reduce the endothelial barrier function via inactivation ofMLC phosphatase (MLCP), leading to increased MLC phosphorylation and actin–myosin contractility (Itoh et al., 1999; Stamatovic et al., 2003). RhoA activation also results in the formation of stress fibers composed of filamentous actin and myosin II (Ridley and Hall, 1992; Wójcik-Stothard et al., 1998; Etienne-Manneville and Hall, 2002). Such mechanisms may contribute, at least in part, to an impaired intracellular movement ofZO-1 and contribute to increased levels of this TJ protein in the nuclear fractions of Tat-stimulated hC-MEC/D3 monolayers.
cells (Fig. 7). In support of this notion, it was demonstrated that cytochalasin B, which interferes with actin polymerization and contractile microfilaments, inhibited ZO-2 migration to the nuclei in MDCK monolayers (Islas et al., 2002). HIV-1 and Tat protein were shown to induce matrix metalloproteinase (MMP) and proteasome activities, which in turn can degrade TJ proteins, including ZO-1 (Huang et al., 2009). Inhibition of both MMP and proteasome activity resulted in attenuation of HIV-1-induced altered expression of ZO-1 (Huang et al., 2009). Thus, nuclear translocation may protect this pool of ZO-1 against proteolytic degradation, whereas the membrane pool remains vulnerable to MMP and proteasome proteolysis. Because membrane ZO-1 is the major form of this TJ protein, its decrease results in diminished levels of total ZO-1 (Fig. 7).

In the present study, inhibition of Rho activity protected against Tat-induced alterations of the total and nuclear ZO-1 levels. In search for a possible target involved in such a protection, we focused on the role of CREB. The rationale for such studies was based on the literature reports indicating that CREB may act as an important transcription factor in regulation of TJ protein expression (Lui et al., 2007). Indeed, computational analysis revealed that ZO-1-promoter contains several potential CREB binding sites (Chen et al., 2008). The role of CREB in ZO-1 expression was also confirmed by demonstrating that transcription factor JunD inhibited TJ protein ZO-1 transcription through binding to the CREB binding site at the ZO-1 promoter (Chen et al., 2008).

CREB is activated through Ser133 phosphorylation, and our data indicate that exposure to Tat both stimulates phosphorylation of CREB and activates its DNA binding activity (Fig. 3). These observations are in agreement with reports that Tat can activate CREB in various cell types, including monocytes and neuronal cells (Williams et al., 2005). Literature data suggest that Tat-induced activation of CREB may be mediated via calmodulin/CaMKII-dependent p38 MAPK. In addition, intracellular Tat has been shown to phosphorylate CREB-1 through regulation of the ERK1/2 MAPK pathway (Gee et al., 2006, 2007). In the present study, we showed that Tat-mediated CREB activation was abolished by C3 adenovirus and ROCK inhibitor Y27632. Another potential mechanism of CREB phosphorylation may involve MLCP. In fact, we recently published that Tat-induced activation of RhoA can inhibit MLCP via phosphorylation of myosin phosphatase target subunit 1 and increased phosphorylation of MLC. Thus, phosphorylation of CREB appears to be placed directly downstream of RhoA. In support of this hypothesis, we demonstrated that CREB immunoprecipitates with MYLK (Fig. 3A) and inhibition of MYLK by ML-9 protected against Tat-induced phosphorylation of CREB (Fig. 3D).

To further evaluate the involvement of CREB in Tat-mediated alterations of ZO-1 expression, CREB was depleted from hCMEC/D3 cells by infection with lentiviral particles containing CREB-specific shRNA. Unexpectedly, depletion of CREB prevented Tat-induced phosphorylation of MLC (Fig. 3E), a downstream kinase in the Rho signaling, indicating that
activation of downstream Rho mediators is dependent on CREB. Thus, our novel results suggest that activation of Rho and CREB are interrelated and regulate in concert ZO-1 expression in response to Tat treatment (Fig. 7). The role of CREB in Tat-mediated alterations of ZO-1 protein was also confirmed in vivo by depletion of this transcription factor from brain microvessels.

Although nuclear localization of TJ proteins has been recognized, its biological significance remains elusive. Nevertheless, evidence indicates that TJ proteins, such as ZO-1 or ZO-2, have functions beyond regulation of endothelial permeability and are also involved in intracellular signaling and gene expression. For example, ZO proteins can associate with regulatory molecules (e.g., with adapter proteins, signaling molecules, or growth factors), thereby modulating the cell cycle. ZO proteins exhibit domains, such as several nuclear localization and nuclear export signals, enabling them to shuttle between the cytoplasm and the nucleus. There is no information available on the role of ZO-1 in the nuclear fraction; however, it might at least partially overlap with that of ZO-2. Literature reports indicate that the ratio between the amount of ZO-2 localizing at TJ and the amount of nuclear ZO-2 adds an additional variable in the control of epithelial cell proliferation and differentiation. Indeed, several studies have suggested that the nuclear localization of ZO-2 depends on the state of cell–cell contacts in epithelial monolayers.

ZO-2 was found to localize at the nucleus primarily in subconfluent epithelial cells before maturation of TJs but gradually exits the nucleus in a leptomycin-sensitive way when the monolayer reaches confluence. Nuclear accumulation of ZO-2 is also believed to be a general response of epithelial and endothelial cells to environmental or mechanical stress because it can be induced by impairing cell–cell contacts by mechanical injury. Transient nuclear expression of ZO-2 has also been observed after heat shock and chemical insults in cerebral endothelial cells and kidney epithelial and endothelial cells (Isla et al., 2002; Traweger et al., 2003). Results of the present study demonstrate that CREB depletion prevents Tat-induced nuclear accumulation of ZO-1 and at the same time attenuates Tat-stimulated endothelial hyperpermeability and enhanced monocyte migration (Fig. 5). Thus, targeting of ZO-1 into the nuclei has profound effects on the functional status of brain endothelial cells.

In summary, the results of the present study demonstrate that exposure to HIV-1 protein Tat results in a decrease in total cellular levels of ZO-1 and an increase in nuclear levels of this TJ protein. Mechanistically, stimulation of Rho signaling and activation of CREB appear to be responsible for triggering nuclear accumulation of ZO-1. Preventing nuclear accumulation of ZO-1 by depletion of CREB attenuated Tat-induced dysfunction of endothelial barrier. Overall, these results indicate the importance of small GTPase, such as Rho, in regulation of TJ protein expression, localization, and modulation of the brain endothelial integrity in the context of HIV-1 brain infection.
References


